Business Plan for Production of Azithromycin, Cefixime, Telmisartan, Diclofenac Sodium, Aceclofenac Active Pharma Ingredients (API) Manufacturing
An active ingredient is that the ingredient during a pharmaceutical drug or pesticide that's biologically active. The similar terms active pharmaceutical ingredient and bulk active also are utilized in medicine, and therefore the term active substance could also be used for natural products. Some medication products may contain more than one active ingredient. The normal word for the active pharmaceutical agent is pharma con or pharm Akon which originally denoted a magical substance or drug.

**Related Project: - [Active Pharma Ingredients](#) • [Azithromycin](#) • [Cefixime](#)
- [Telmisartan](#) • [Diclofenac Sodium](#) • [Aceclofenac](#)
The terms active constituent or active principle are often chosen when pertaining to the active substance of interest during a plant (such as 2-hydroxybenzoic acid in willow bark or are choline in areca nuts), because the word ingredient in many minds connotes a way of human agency (that is, something that an individual combines with other substances), whereas the natural products present in plants weren't added by any human agency but rather occurred naturally ("a plant doesn't have ingredients").

**Related Projects:** - Active Pharmaceutical Ingredient (API) Products, Bulk API Manufacturing
Azithromycin is an antibiotic used for the treatment of variety of bacterial infections. This includes middle ear infections, streptococcus tonsillitis, pneumonia, traveler's diarrhea, and certain other intestinal infections. It also can be used for variety of sexually transmitted infections, including chlamydia and gonorrhea infections. Alongside other medications, it's going to even be used for malaria. It are often taken by mouth or intravenously with doses once per day.

Cefixime, an antibiotic, may be a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is very stable within the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and a few cephalosporins because of the presence of beta-lactamases, could also be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopentide synthesis within the bacterial cell wall.
Cefixime, sold under the brand name Surtax among others, is an antibiotic medication won’t to treat variety of bacterial infections. These infections include otitis, strep throat, pneumonia, tract infections, gonorrhea, and lyme disease. For gonorrhea typically just one dose is required. Within the us it’s a second-line treatment to ceftriaxone for gonorrhea. It’s taken by mouth.

**Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks**

Telmisartan, sold under the brand name Micardis among others, may be a medication used to treat high blood pressure, heart failure, and diabetic renal disorder. It’s an inexpensive initial treatment for top blood pressure. It’s taken orally. Versions are available because the combination telmisartan/hydrochlorothiazide and telmisartan / amlodipine.
Diclofenac, sold under the name Voltaren among others, may be a nonsteroidal anti-inflammatory drug (NSAID) wont to treat pain and inflammatory diseases like gout. It’s taken by mouth, rectally during a suppository, employed by injection, or applied to the skin. Improvements in pain last for the maximum amount as eight hours. It’s also available in combination with misoprostol in an effort to decrease stomach problems. Aceclofenac may be a nonsteroidal anti-inflammatory drug (NSAID) analog of diclofenac. It’s used for the relief of pain and inflammation in rheumatoid arthritis, osteoarthritis and ankylosing spondylitis.

**Related Project:** - Active Pharma Ingredients • Azithromycin • Cefixime • Telmisartan • Diclofenac Sodium • Aceclofenac
Role of Government towards API

The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively.

Related Videos: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs
The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc.

The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years.

Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years.
Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs.

Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs.

The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years.

The drug industry has welcomed the incentives offered by the government to promote API units in India.

Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore.
The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices.

Projects: - Project Reports & Profiles
Union Cabinet scheme on Promotion of Bulk Drug Parks

• The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years.

• Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years.

Projects: - Project Reports & Profiles
Details:
Promotion of Bulk Drug Parks

• Decision is to develop 3 mega Bulk Drug parks in India in partnership with States.
• Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park.
• Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc.
• A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years.

Books: - Books & Databases
Production Linked Incentive Scheme

• Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years.

• Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs.

• Rate of incentive will be 20% (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs.

• A sum of Rs. 6,940 crore has been approved for next 8 years.

Market Research Reports: - Market Research Reports, India and Global Industry Analysis, Market Trends
Active pharmaceutical ingredients are an active ingredient of any drug or tablet, which possesses medicinal properties. Some drugs with combined therapy have many active ingredients to treat different disorders. The increasing occurrences of chronic diseases, growth in abbreviated new drug applications (ANDA), rising acceptance and uptake of biopharmaceuticals, and the growing importance of generics across the globe is expected to enhance the Active Pharmaceutical Ingredients Market growth. However, the stringent regulatory policies and adverse drug price control policies across numerous countries are likely to curb the growth of the market.

Projects: - Project Reports & Profiles
The API market is surging due to the increased demand for pharmaceutical drugs, which in turn is driven by the aging population, rising prevalence of chronic diseases such as cancer, diabetes, cardiovascular, neurological and infectious diseases. India and China are the major suppliers of APIs to North America due to their low production capacities, labor costs and the presence of a large number of global and domestic players. In order to cut down on expenses and increase profits, companies have begun outsourcing the creation of APIs to the developing countries in Asia, leading to growth in the Asian market.

Books: - Books & Databases
Rise in demand for new drugs at a low cost and entry of domestic and global companies in the APIs market have led to innovative product offerings with new and advanced techniques. Any substance or combination of substances used in a finished pharmaceutical product (FPP) is known as active pharmaceutical ingredients (API). High-potency active pharmaceutical ingredients (HPAPIs) and antibody-drug conjugates are recent innovations in the market and require a special manufacturing set up. Most of these drugs are used in oncology. A large number of patents for small molecule APIs are expected to expire in the next few years, with many drugs losing patent protection in 2018. This is estimated to unlock a significant market opportunity for generic drug manufacturers, resulting in augmented demand for APIs.

Projects: - [Project Reports & Profiles](#)
Higher Growth

Healthcare spending has witnessed continued growth for some time now. Even though the proportion of healthcare spending in the APAC region is comparatively low, the growth rate in this strategic region has outpaced that of mature markets in North America and Europe. Rising healthcare spending has led to quality healthcare becoming accessible along with a higher demand for pharmaceutical products across APAC. The pharmaceuticals consumed here are mostly produced in onshore manufacturing units. Furthermore, contract manufacturing organizations are key outsourcing allies for pharmaceutical companies that supply their wares to North America and Europe.

Projects: - Project Reports & Profiles
Market Segmentations

- Based on manufacturing process, the Global Active Pharmaceutical Ingredients Market has been segmented into captive manufacturing and contract manufacturing.

- Based on type of synthesis, the Global Active Pharmaceutical Ingredients Market has been segmented into synthetic and biotech. On the basis of biotech synthesis, the market is further sub-segmented into monoclonal antibodies, recombinant proteins, vaccines, and others.

- Based on API formulation, the Global Active Pharmaceutical Ingredients Market has been divided into generic API and branded/innovative API.

Market Research Reports: - Market Research Reports, India and Global Industry Analysis, Market Trends
- Based on application, the global market is segmented into cardiovascular disease, oncology, neurological disorders, orthopedic disorders, respiratory, gastrointestinal disorders, urology, and others.
- Based on molecule, the global Active Pharmaceutical Ingredients Market is divided into large molecule and small molecule.

Related Project: - Active Pharma Ingredients • Azithromycin • Cefixime • Telmisartan • Diclofenac Sodium • Aceclofenac
Global Active Pharmaceutical Ingredient Market Dynamics

The key factor for growth of worldwide Active Pharmaceutical Ingredient market is that the rise of demand for the new drug discovery for treatment of various chronic and infectious diseases like HIV, cancer, arthritis, bone & joint infections, hepatitis-B, Aids etc. across the world. According to WHO in 2018, the worldwide cancer burden has risen to 18.1 million new cases including 9.6 million deaths across the world. Because of such rise within the cases of cancer, the new drugs discovery using the Active Pharmaceutical Ingredient has become essential. Recently consistent with the American Chemical Society in 2019, there has been 48 new drugs has been approved by the FDA U.S. out of which 11 for brand new cancer treatments with the innovative molecular pharmaceutical ingredients.
However, the **Active Pharmaceutical Ingredient** market is hampered by need for prime investment with huge capital requirement for research and developments. Moreover rising health cautiousness among the people with technological advancement huge investment for launching of recent drugs and biological products, acquisitions, collaborations, and regional expansion will provide huge opportunity for **Active Pharmaceutical Ingredient** market.

Active Pharmaceutical Ingredients are chemically and biologically active components of medicine with direct effect in cure, mitigation, treatment and prevention of diseases. The worldwide API market has witnessed tremendous growth over the previous couple of decades because of the increased use of medicine and biologics within the treatment of diseases.
On the opposite hand, the API industry is facing the challenges such as, shortening the event time, reducing the value of development, improving the method design and meeting the standard without compromising on the profitability. The worldwide API market is probably going to be impacted by an outsized number of innovative drugs going off patent within the recent years. There’s an impending need for technological innovations to take care of the profitability in high volume and a coffee value environment. The most important factors driving the market growth are, rising incidences of oncology, cardiovascular, diabetes and lifestyle diseases, rising number of hospitals and diagnostic centers, rising geriatric population in developing countries, increasing healthcare expenditure, increasing disease awareness and education. However, a scarcity of skilled workforce and limited accessibility of medicine within the developing countries are likely to restrict the market growth.
The global active pharmaceutical ingredient market size is expected to reach a value of USD 286.6 billion by 2027, registering a CAGR of 6.7% over the forecast period. Factors, such as increasing preference for outsourcing APIs and growing prevalence of various target diseases such as cancer and Cardiovascular Diseases (CVDs) are expected to drive the market growth. The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years.

Market Research Reports: - Market Research Reports, India and Global Industry Analysis, Market Trends
Key Players:-

- Alpha Remedies Ltd.
- Ankur Drugs & Pharma Ltd.
- Aurobindo Pharma Ltd.
- Cian Healthcare Ltd
- Cipla Ltd.
- Dr. Reddy'S Laboratories Ltd.
- Farmson Pharmaceutical Gujarat Pvt. Ltd.
- Glaxosmithkline Pharmaceuticals Ltd.
- Indoco Remedies Ltd.
- Pan Drugs Ltd.
- Piramal Enterprises Ltd.
- Sanofi India Ltd.
- Sri Krishna Pharmaceuticals Ltd.
- Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd.
- Triton Laboratories Ltd.
Machinery Photographs

Jacketed Reactor

Filter

www.entrepreneurindia.co

www.niir.org
Fluidised Bed Dryer

Distillation Assembly
# Project at a Glance

<table>
<thead>
<tr>
<th>COST OF PROJECT</th>
<th>MEANS OF FINANCE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Particulars</strong></td>
<td><strong>Existing</strong></td>
</tr>
<tr>
<td>Land &amp; Site Development Exp.</td>
<td>0.00</td>
</tr>
<tr>
<td>Buildings</td>
<td>0.00</td>
</tr>
<tr>
<td>Plant &amp; Machineries</td>
<td>0.00</td>
</tr>
<tr>
<td>Motor Vehicles</td>
<td>0.00</td>
</tr>
<tr>
<td>Office Automation Equipments</td>
<td>0.00</td>
</tr>
<tr>
<td>Technical Knowhow Fees &amp; Exp.</td>
<td>0.00</td>
</tr>
<tr>
<td>Franchise &amp; Other Deposits</td>
<td>0.00</td>
</tr>
<tr>
<td>Preliminary &amp; Pre-operative Exp</td>
<td>0.00</td>
</tr>
<tr>
<td>Provision for Contingencies</td>
<td>0.00</td>
</tr>
<tr>
<td>Margin Money - Working Capital</td>
<td>0.00</td>
</tr>
<tr>
<td>TOTAL</td>
<td>0.00</td>
</tr>
</tbody>
</table>
## Project at a Glance

<table>
<thead>
<tr>
<th>Year</th>
<th>Annualised Book Value</th>
<th>Debt</th>
<th>Dividend</th>
<th>Retained Earnings</th>
<th>Payout</th>
<th>Probable Market Price</th>
<th>P/E Ratio</th>
<th>Yield Price/Book Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EPS</td>
<td>CEPS</td>
<td>Per Share</td>
<td>Per Share</td>
<td>%</td>
<td>%</td>
<td>No.of Times</td>
<td>%</td>
</tr>
<tr>
<td>1-2</td>
<td>6.69</td>
<td>9.49</td>
<td>16.69</td>
<td>24.00</td>
<td>0.00</td>
<td>100.0</td>
<td>0</td>
<td>6.69</td>
</tr>
<tr>
<td>2-3</td>
<td>9.43</td>
<td>11.89</td>
<td>26.12</td>
<td>18.00</td>
<td>0.00</td>
<td>100.0</td>
<td>0</td>
<td>9.43</td>
</tr>
<tr>
<td>3-4</td>
<td>12.30</td>
<td>14.45</td>
<td>38.42</td>
<td>12.00</td>
<td>0.00</td>
<td>100.0</td>
<td>0</td>
<td>12.30</td>
</tr>
<tr>
<td>4-5</td>
<td>15.05</td>
<td>16.94</td>
<td>53.47</td>
<td>6.00</td>
<td>0.00</td>
<td>100.0</td>
<td>0</td>
<td>15.05</td>
</tr>
<tr>
<td>5-6</td>
<td>17.65</td>
<td>19.32</td>
<td>71.12</td>
<td>0.00</td>
<td>0.00</td>
<td>100.0</td>
<td>0</td>
<td>17.65</td>
</tr>
</tbody>
</table>
## Project at a Glance

<table>
<thead>
<tr>
<th>Year</th>
<th>D. S. C. R.</th>
<th>Debt / Deposits</th>
<th>Equity as- Equity</th>
<th>Total Net Worth</th>
<th>Return on Net Worth</th>
<th>Profitability Ratio</th>
<th>Assets Turnover Ratio</th>
<th>Current Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Individu, Cumulative, Overall</td>
<td>(Number of times)</td>
<td>(Number of times)</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Initial</td>
<td>3.00</td>
<td>3.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-2</td>
<td>1.40</td>
<td>1.40</td>
<td>1.44</td>
<td>1.44</td>
<td>7.54</td>
<td></td>
<td>3.19%</td>
<td>1.49%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1014.16</td>
<td>8.31%</td>
</tr>
<tr>
<td>2-3</td>
<td>1.72</td>
<td>1.55</td>
<td>0.69</td>
<td>0.69</td>
<td>5.19</td>
<td></td>
<td>3.47%</td>
<td>1.87%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>991.33</td>
<td>6.96%</td>
</tr>
<tr>
<td>3-4</td>
<td>2.12</td>
<td>1.73</td>
<td>2.11</td>
<td>0.31</td>
<td>3.81</td>
<td></td>
<td>3.65%</td>
<td>2.16%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1128.38</td>
<td>6.93%</td>
</tr>
<tr>
<td>4-5</td>
<td>2.57</td>
<td>1.91</td>
<td>0.11</td>
<td>0.11</td>
<td>2.94</td>
<td></td>
<td>3.77%</td>
<td>2.36%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1265.43</td>
<td>6.91%</td>
</tr>
<tr>
<td>5-6</td>
<td>3.09</td>
<td>2.11</td>
<td>0.00</td>
<td>0.00</td>
<td>2.36</td>
<td></td>
<td>3.84%</td>
<td>2.50%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1402.48</td>
<td>6.90%</td>
</tr>
</tbody>
</table>
## Project at a Glance

<table>
<thead>
<tr>
<th>BEP</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BEP - Maximum Utilisation Year</strong></td>
<td>5</td>
</tr>
<tr>
<td><strong>Cash BEP (% of Installed Capacity)</strong></td>
<td>59.30%</td>
</tr>
<tr>
<td><strong>Total BEP (% of Installed Capacity)</strong></td>
<td>61.47%</td>
</tr>
</tbody>
</table>

### IRR, PAYBACK and FACR

<table>
<thead>
<tr>
<th>Internal Rate of Return .. ( In %age )</th>
<th>31.15%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Payback Period of the Project is</td>
<td>2 Years 3 Months</td>
</tr>
<tr>
<td>Fixed Assets Coverage Ratio ( No. of times )</td>
<td>86.957</td>
</tr>
</tbody>
</table>
1. What is Active Pharma Ingredients (API) Manufacturing industry?

2. How has the Active Pharma Ingredients (API) Manufacturing industry performed so far and how will it perform in the coming years?

3. What is the Project Feasibility of Active Pharma Ingredients (API) Manufacturing Plant?

4. What are the requirements of Working Capital for setting up Active Pharma Ingredients (API) Manufacturing plant?
5. What is the structure of the Active Pharma Ingredients (API) Manufacturing Business and who are the key/major players?

6. What is the total project cost for setting up Active Pharma Ingredients (API) Manufacturing Business?

7. What are the operating costs for setting up Active Pharma Ingredients (API) Manufacturing plant?

8. What are the machinery and equipment requirements for setting up Active Pharma Ingredients (API) Manufacturing plant?
9. Who are the Suppliers and Manufacturers of Plant & Machinery for setting up Active Pharma Ingredients (API) Manufacturing plant?

10. What are the requirements of raw material for setting up Active Pharma Ingredients (API) Manufacturing plant?

11. Who are the Suppliers and Manufacturers of Raw materials for setting up Active Pharma Ingredients (API) Manufacturing Business?

12. What is the Manufacturing Process of Active Pharma Ingredients (API)?
13. What is the total size of land required for setting up Active Pharma Ingredients (API) Manufacturing plant?

14. What will be the income and expenditures for Active Pharma Ingredients (API) Manufacturing Business?

15. What are the Projected Balance Sheets of Active Pharma Ingredients (API) Manufacturing plant?

16. What are the requirement of utilities and overheads for setting up Active Pharma Ingredients (API) Manufacturing plant?

17. What is the Built up Area Requirement and cost for setting up Active Pharma Ingredients (API) Manufacturing Business?
18. What are the Personnel (Manpower) Requirements for setting up Active Pharma Ingredients (API) Manufacturing Business?

19. What are Statistics of Import & Export for Active Pharma Ingredients (API)?

20. What is the time required to break-even of Active Pharma Ingredients (API) Manufacturing Business?

21. What is the Break-Even Analysis of Active Pharma Ingredients (API) Manufacturing plant?

22. What are the Project financials of Active Pharma Ingredients (API) Manufacturing Business?

www.niir.org

www.entrepreneurindia.co
23. What are the Profitability Ratios of Active Pharma Ingredients (API) Manufacturing Project?

24. What is the Sensitivity Analysis-Price/Volume of Active Pharma Ingredients (API) Manufacturing plant?

25. What are the Projected Pay-Back Period and IRR of Active Pharma Ingredients (API) Manufacturing plant?

26. What is the Process Flow Sheet Diagram of Active Pharma Ingredients (API) Manufacturing project?
27. What are the Market Opportunities for setting up Active Pharma Ingredients (API) Manufacturing plant?

28. What is the Market Study and Assessment for setting up Active Pharma Ingredients (API) Manufacturing Business?

29. What is the Plant Layout for setting up Active Pharma Ingredients (API) Manufacturing Business?
Table of Contents of the Project Report
1. **PROJECT LOCATION**

1.1. **DISTRICT PROFILE & GEOTECHNICAL SITE CHARACTERIZATION**

1.1.1. General

1.1.2. Physical Characteristics

1.1.3. Climate & Rainfall

1.1.4. Map

1.1.5. Economy & Industry

1.1.6. Transportation and Communications

2. **INTRODUCTION**
3. **AZITHROMYCIN**

3.1. MEDICAL USES

3.2. CHEMICAL AND PHYSICAL DATA

3.3. RAW MATERIAL

3.4. MANUFACTURING PROCESS

3.5. PROCESS FLOW DIAGRAM

4. **CEFIXIME**

4.1. MEDICAL USES

4.2. PHYSICAL PROPERTIES

4.3. RAW MATERIAL

4.4. MANUFACTURING PROCESS

4.5. PROCESS FLOW DIAGRAM
5. **TELMISARTAN**
   5.1. MEDICAL USES
   5.2. CHEMICAL PROPERTIES
   5.3. PHYSICAL PROPERTIES
   5.4. RAW MATERIAL
   5.5. MANUFACTURING PROCESS
   5.6. PROCESS FLOW DIAGRAM

6. **DICLOFENAC SODIUM**
   6.1. MEDICAL USES
   6.2. FORMULATIONS AND TRADE NAMES
   6.3. PROPERTIES
   6.4. RAW MATERIALS
   6.5. MANUFACTURING PROCESS
   6.6. PROCESS FLOW DIAGRAM
7. ACECLOFENAC
   7.1. CHEMISTRY
   7.2. CHEMICAL AND PHYSICAL DATA
   7.3. RAW MATERIALS
   7.4. MANUFACTURING PROCESS

8. PROCESS FLOW DIAGRAM

9. MARKET SURVEY
   9.1. ABOUT THE GEOGRAPHY
   9.2. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
       9.2.1. Further Key Findings from the Study Suggest
       9.2.2. Industry Insights
       9.2.3. Application Insights
       9.2.4. Regional Insights
       9.2.5. Market Share Insights
9.3. KEY PLAYERS IN THE GLOBAL APIs MARKET
9.4. SPECIALTY MEDICINES

9.5. KEY PLAYERS FOR GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT SERVICES MARKET REPORTS

9.6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT
9.6.1. Market Dynamics
9.6.2. Regional Analysis
9.6.3. Drivers and Key Restraints
9.6.4. Market Studied By Top Companies
9.6.5. Market Trends

9.7. INCREASING COMPETITION IN THE API MARKET
9.7.1. Market Segmentation
9.7.2. Regional Outlook
9.7.3. Market Dynamics
9.7.4. Market Segmentations
9.7.5. Regional Analysis

9.8. MARKET KEY PLAYERS
10. MAJOR FIVE ACTIVE PHARMACEUTICAL INGREDIENTS COMPANIES

11. EXPORT & IMPORT: ALL COUNTRIES
11.1. EXPORT: ALL COUNTRIES
11.2. IMPORT: ALL COUNTRIES

12. FINANCIALS & COMPARISON OF MAJOR INDIAN PLAYERS/COMPANIES
12.1. ABOUT FINANCIAL STATEMENTS OF CMIE DATABASE
12.2. PROFITS & APPROPRIATIONS
12.3. TOTAL LIABILITIES
12.4. TOTAL ASSETS
12.5. NET CASH FLOW FROM OPERATING ACTIVITIES
12.6. SECTION –I
12.6.1. Name of Company with Contact Details
12.6.2. Name of Director(S)
12.6.3. Plant Capacity
12.6.4. Location of Plant
12.6.5. Credit Ratings
12.6.6. Name of Raw Material(S) Consumed with Quantity & Cost

12.7. SECTION-II
12.7.1. Assets
12.7.2. Cash Flow
12.7.3. Cost as % Ge of Sales
12.7.4. Forex Transaction
12.7.5. Growth in Assets & Liabilities
12.7.6. Growth in Income & Expenditure
12.7.7. Income & Expenditure
12.7.8. Liabilities
12.7.9. Liquidity Ratios
12.7.10. Profitability Ratio
12.7.11. Profits
12.7.12. Return Ratios
12.7.13. Structure of Assets & Liabilities(%) 
12.7.14. Working Capital & Turnover Ratios

13. COMPANY PROFILE OF MAJOR PLAYERS

14. EXPORT & IMPORT STATISTICS OF INDIA

14.1. EXPORT STATISTICS ON ACTIVE PHARMACEUTICAL INGREDIENTS
14.2. IMPORT STATISTICS ON ACTIVE PHARMACEUTICAL INGREDIENTS
15. PRESENT MANUFACTURERS

16. BUYER’S LIST
   16.1. CONTACT DETAILS OF BUYER’S
   16.2. NAME OF DIRECTOR(S)
   16.3. PLANT CAPACITY
   16.4. CREDIT RATINGS
   16.5. COMPANY WISE CONSUMPTION DETAIL OF THE RAW MATERIALS

17. SUPPLIERS OF PLANT & MACHINERY

18. SUPPLIERS OF RAW MATERIAL
19. PHOTOGRAPHS/IMAGES FOR REFERENCE

19.1. MACHINERY PHOTOGRAPHS

19.2. RAW MATERIAL PHOTOGRAPHS

19.3. PRODUCT PHOTOGRAPHS

20. PLANT LAYOUT
Project Financials

• Project at a Glance

• Assumptions for Profitability workings ..................................................1
• Plant Economics..................................................................................................2
• Production Schedule...........................................................................................3
• Land & Building.................................................................................................4

Factory Land & Building
Site Development Expenses
• Plant & Machinery

  Indigenous Machineries
  Other Machineries (Miscellaneous, Laboratory etc.)

• Other Fixed Assets

  Furniture & Fixtures
  Pre-operative and Preliminary Expenses
  Technical Knowhow
  Provision of Contingencies

• Working Capital Requirement Per Month

  Raw Material
  Packing Material
  Lab & ETP Chemical Cost
  Consumable Store
• Overheads Required Per Month and Per Annum..........................8
  Utilities & Overheads (Power, Water and Fuel Expenses etc.)
  Royalty and Other Charges
  Selling and Distribution Expenses

• Salary and Wages .................................................................9

• Turnover Per Annum ............................................................10

• Share Capital.......................................................................11
  Equity Capital
  Preference Share Capital
• Annexure 1 :: Cost of Project and Means of Finance

• Annexure 2 :: Profitability and Net Cash Accruals

- Revenue/Income/Realisation
- Expenses/Cost of Products/Services/Items
- Gross Profit
- Financial Charges
- Total Cost of Sales
- Net Profit After Taxes
- Net Cash Accruals
• Annexure 3 :: Assessment of Working Capital requirements

- Current Assets
- Gross Working Capital
- Current Liabilities
- Net Working Capital
- Working Note for Calculation of Work-in-process

• Annexure 4 :: Sources and Disposition of Funds
• Annexure 5 :: Projected Balance Sheets

- ROI (Average of Fixed Assets)
- RONW (Average of Share Capital)
- ROI (Average of Total Assets)

• Annexure 6 :: Profitability Ratios

- D.S.C.R
- Earnings Per Share (EPS)
- Debt Equity Ratio
Annexure 7 :: Break-Even Analysis

- Variable Cost & Expenses
- Semi-Variable/Semi-Fixed Expenses
- Profit Volume Ratio (PVR)
- Fixed Expenses / Cost
- B.E.P
Annexure 8 to 11 :: Sensitivity Analysis-Price/Volume

- Resultant N.P.B.T
- Resultant D.S.C.R
- Resultant PV Ratio
- Resultant DER
- Resultant ROI
- Resultant BEP
• **Annexure 12 :: Shareholding Pattern and Stake Status**
  - **Equity Capital**
  - **Preference Share Capital**
• **Annexure 13 :: Quantitative Details-Output/Sales/Stocks**
  - Determined Capacity P.A of Products/Services
  - Achievable Efficiency/Yield % of Products/Services/Items
  - Net Usable Load/Capacity of Products/Services/Items
  - Expected Sales/ Revenue/ Income of Products/ Services/ Items
Annexure 14 :: Product wise Domestic Sales Realisation

Annexure 15 :: Total Raw Material Cost

Annexure 16 :: Raw Material Cost per unit

Annexure 17 :: Total Lab & ETP Chemical Cost

Annexure 18 :: Consumables, Store etc.

Annexure 19 :: Packing Material Cost

Annexure 20 :: Packing Material Cost Per Unit
• Annexure 21 :: Employees Expenses
• Annexure 22 :: Fuel Expenses
• Annexure 23 :: Power/Electricity Expenses
• Annexure 24 :: Royalty & Other Charges
• Annexure 25 :: Repairs & Maintenance Expenses
• Annexure 26 :: Other Manufacturing Expenses
• Annexure 27 :: Administration Expenses
• Annexure 28 :: Selling Expenses
• Annexure 29 :: Depreciation Charges – as per Books (Total)
• Annexure 30 :: Depreciation Charges – as per Books (P & M)
• Annexure 31 :: Depreciation Charges - as per IT Act WDV (Total)
• Annexure 32 :: Depreciation Charges - as per IT Act WDV (P & M)
• Annexure 33 :: Interest and Repayment - Term Loans
• Annexure 34 :: Tax on Profits
• Annexure 35 :: Projected Pay-Back Period and IRR
Reasons for Buying our Report:

• This report helps you to identify a profitable project for investing or diversifying into by throwing light to crucial areas like industry size, market potential of the product and reasons for investing in the product
• This report provides vital information on the product like it’s characteristics and segmentation
• This report helps you market and place the product correctly by identifying the target customer group of the product
• This report helps you understand the viability of the project by disclosing details like machinery required, project costs and snapshot of other project financials

• The report provides a glimpse of government regulations applicable on the industry

• The report provides forecasts of key parameters which helps to anticipate the industry performance and make sound business decisions
Our Approach:

• Our research reports broadly cover Indian markets, present analysis, outlook and forecast for a period of five years.

• The market forecasts are developed on the basis of secondary research and are cross-validated through interactions with the industry players.

• We use reliable sources of information and databases. And information from such sources is processed by us and included in the report.
Scope of the Report

The report titled “Market Survey cum Detailed Techno Economic Feasibility Report on Active Pharma Ingredients (API).” provides an insight into Active Pharma Ingredients (API) market in India with focus on uses and applications, Manufacturing Process, Process Flow Sheets, Plant Layout and Project Financials of Active Pharma Ingredients (API) project. The report assesses the market sizing and growth of the Indian Active Pharma Ingredients (API) Industry. While expanding a current business or while venturing into new business, entrepreneurs are often faced with the dilemma of zeroing in on a suitable product/line. And before diversifying/venturing into any product, they wish to study the following aspects of the identified product:

www.entrepreneurindia.co
• Good Present/Future Demand
• Export-Import Market Potential
• Raw Material & Manpower Availability
• Project Costs and Payback Period

We at NPCS, through our reliable expertise in the project consultancy and market research field, have demystified the situation by putting forward the emerging business opportunity in the Active Pharma Ingredients (API) sector in India along with its business prospects. Through this report we have identified Active Pharma Ingredients (API) project as a lucrative investment avenue.
#APIBusiness #apimanufacturing #Apiproduction #APImarket #APIProject
_ApiStartup_ #APIindustry #Activepharmaingredients #pharmaingredients
#IndianPharma, #medicineingredients #CoronavirusBusiness #COVID2019
#Activepharmaingredientbusinessplan #APIbusinessplan #APIbusinessidea
#startupAPIbusiness #Activepharmaingredientmanufacturing
#APIproduction #APIBusinessplan #Azithromycin #Cefixime #Telmisartan
#Diclofenacsodium #Aceclofenac #DetailedProjectReport
#businessconsultant #BusinessPlan #feasibilityReport #NPCS
#entrepreneurindia #startupbusiness #startupbusinessideas
#howtostartbusiness #InvestInStartups #Plan4Business #StartupProject
#ProjectReport #startupplan #BusinessKaiseshurukare
#BusinessProjectReport
**NIIR Project Consultancy Services (NPCS)**
can provide Detailed Project Report on

**Active Pharma Ingredients (API) • Azithromycin • Cefixime • Telmisartan • Diclofenac Sodium • Aceclofenac**

**See more**

**Project Reports & Profiles**

**BOOKS**

**Market Research Report**
Visit us at

www.entrepreneurindia.co

www.niir.org
Take a look at Niir Project Consultancy Services on #Street View
https://goo.gl/VstWkd

Locate us on Google Maps
https://goo.gl/maps/BKkUtq9gevT2
Our inexhaustible Client list includes public-sector companies, Corporate Houses, Government undertaking, individual entrepreneurs, NRI, Foreign investors, non-profit organizations and educational institutions from all parts of the World. The list is just a glimpse of our esteemed & satisfied Clients.

Click here to take a look
https://goo.gl/G3ICjV
Select and Choose the Right Business Startup for You

(Instant Online Project Identification and Selection)

Finding the right startup business is one of the most popular subject today. Starting a business is no easy endeavor, but the time, effort, and challenges can be worth it if you succeed. To give yourself the best chance to be successful, take your time to carefully find the right business for you. We, at NPCS, endeavor to make business selection a simple and convenient step for any entrepreneur/startup. Our expert team, by capitalizing on its dexterity and decade's long experience in the field, has created a list of profitable ventures for entrepreneurs who wish to diversify or venture. The list so mentioned is updated regularly to give you a regular dose of new emerging opportunities.

Visit: https://www.entrepreneurindia.co/project-identification
Download Complete List of Project Reports:

- Detailed Project Reports

Visit: https://www.entrepreneurindia.co/complete-project-list

NPCS is manned by engineers, planners, specialists, financial experts, economic analysts and design specialists with extensive experience in the related industries.

Our Market Survey cum Detailed Techno Economic Feasibility Report provides an insight of market in India. The report assesses the market sizing and growth of the Industry. While expanding a current business or while venturing into new business, entrepreneurs are often faced with the dilemma of zeroing in on a suitable product/line.
And before diversifying/venturing into any product, they wish to study the following aspects of the identified product:

- **Good Present/Future Demand**
- **Export-Import Market Potential**
- **Raw Material & Manpower Availability**
- **Project Costs and Payback Period**

The detailed project report covers all aspect of business, from analyzing the market, confirming availability of various necessities such as Manufacturing Plant, Detailed Project Report, Profile, Business Plan, Industry Trends, Market Research, Survey, Manufacturing Process, Machinery, Raw Materials, Feasibility Study, Investment Opportunities, Cost and Revenue, Plant Economics, Production Schedule,
Working Capital Requirement, uses and applications, Plant Layout, Project Financials, Process Flow Sheet, Cost of Project, Projected Balance Sheets, Profitability Ratios, Break Even Analysis. The DPR (Detailed Project Report) is formulated by highly accomplished and experienced consultants and the market research and analysis are supported by a panel of experts and digitalized data bank.

We at NPCS, through our reliable expertise in the project consultancy and market research field, have demystified the situation by putting forward the emerging business opportunity in India along with its business prospects......Read more
Contact us

Niir Project Consultancy Services

106-E, Kamla Nagar, Opp. Mall ST,
New Delhi-110007, India.

Email: npcs.ei@gmail.com , info@entrepreneurindia.co

Tel: +91-11-23843955, 23845654, 23845886
Mobile: +91-9097075054, 8800733955
Fax: +91-11-23845886

Website : www.entrepreneurindia.co , www.niir.org

Take a look at Niir Project Consultancy Services on #StreetView

https://goo.gl/VstWkd
Who are we?

- One of the leading reliable names in industrial world for providing the most comprehensive technical consulting services

- We adopt a systematic approach to provide the strong fundamental support needed for the effective delivery of services to our Clients’ in India & abroad
We at NPCS want to grow with you by providing solutions scale to suit your new operations and help you reduce risk and give a high return on application investments. We have successfully achieved top-notch quality standards with a high level of customer appreciation resulting in long lasting relation and large amount of referral work through technological breakthrough and innovative concepts. A large number of our Indian, Overseas and NRI Clients have appreciated our expertise for excellence which speaks volumes about our commitment and dedication to every client's success.
We bring deep, functional expertise, but are known for our holistic perspective: we capture value across boundaries and between the silos of any organization. We have proven a multiplier effect from optimizing the sum of the parts, not just the individual pieces. We actively encourage a culture of innovation, which facilitates the development of new technologies and ensures a high quality product.
What do we offer?

- Project Identification
- Detailed Project Reports/Pre-feasibility Reports
- Market Research Reports
- Business Plan
- Technology Books and Directory
- Industry Trend
- Databases on CD-ROM
- Laboratory Testing Services
- Turnkey Project Consultancy/Solutions
- Entrepreneur India (An Industrial Monthly Journal)
How are we different?

- We have two decades long experience in project consultancy and market research field.
- We empower our customers with the prerequisite know-how to take sound business decisions.
- We help catalyze business growth by providing distinctive and profound market analysis.
- We serve a wide array of customers, from individual entrepreneurs to Corporations and Foreign Investors.
- We use authentic & reliable sources to ensure business precision.

www.niir.org

www.entrepreneurindia.co
Our Approach

Requirement collection

Thorough analysis of the project

Economic feasibility study of the Project

Market potential survey/research

Report Compilation

www.entrepreneurindia.co

www.niir.org
Who do we Serve?

- Public-sector Companies
- Corporates
- Government Undertakings
- Individual Entrepreneurs
- NRI’s
- Foreign Investors
- Non-profit Organizations, NBFC’s
- Educational Institutions
- Embassies & Consulates
- Consultancies
- Industry / trade associations
Sectors We Cover

- Ayurvedic And Herbal Medicines, Herbal Cosmetics
- Alcoholic And Non Alcoholic Beverages, Drinks
- Adhesives, Industrial Adhesive, Sealants, Glues, Gum & Resin
- Activated Carbon & Activated Charcoal
- Aluminium And Aluminium Extrusion Profiles & Sections,
- Bio-fertilizers And Biotechnology
- Breakfast Snacks And Cereal Food
- Bicycle Tyres & Tubes, Bicycle Parts, Bicycle Assembling
## Sectors We Cover

- Bamboo And Cane Based Projects
- Building Materials And Construction Projects
- Biodegradable & Bioplastic Based Projects
- Chemicals (Organic And Inorganic)
- Confectionery, Bakery/Baking And Other Food
- Cereal Processing
- Coconut And Coconut Based Products
- Cold Storage For Fruits & Vegetables
- Coal & Coal Byproduct
Sectors We Cover

- Copper & Copper Based Projects
- Dairy/Milk Processing
- Disinfectants, Pesticides, Insecticides, Mosquito Repellents,
- Electrical, Electronic And Computer based Projects
- Essential Oils, Oils & Fats And Allied
- Engineering Goods
- Fibre Glass & Float Glass
- Fast Moving Consumer Goods
- Food, Bakery, Agro Processing
Sectors We Cover

- Fruits & Vegetables Processing
- Ferro Alloys Based Projects
- Fertilizers & Biofertilizers
- Ginger & Ginger Based Projects
- Herbs And Medicinal Cultivation And Jatropha (Biofuel)
- Hotel & Hospitality Projects
- Hospital Based Projects
- Herbal Based Projects
- Inks, Stationery And Export Industries
Sectors We Cover

- Infrastructure Projects
- Jute & Jute Based Products
- Leather And Leather Based Projects
- Leisure & Entertainment Based Projects
- Livestock Farming Of Birds & Animals
- Minerals And Minerals
- Maize Processing (Wet Milling) & Maize Based Projects
- Medical Plastics, Disposables Plastic Syringe, Blood Bags
- Organic Farming, Neem Products Etc.
Sectors We Cover  cont...

- Paints, Pigments, Varnish & Lacquer
- Paper And Paper Board, Paper Recycling Projects
- Printing Inks
- Packaging Based Projects
- Perfumes, Cosmetics And Flavours
- Power Generation Based Projects & Renewable Energy Based Projects
- Pharmaceuticals And Drugs
- Plantations, Farming And Cultivations
- Plastic Film, Plastic Waste And Plastic Compounds
- Plastic, PVC, PET, HDPE, LDPE Etc.
Sectors We Cover

- Potato And Potato Based Projects
- Printing And Packaging
- Real Estate, Leisure And Hospitality
- Rubber And Rubber Products
- Soaps And Detergents
- Stationary Products
- Spices And Snacks Food
- Steel & Steel Products
- Textile Auxiliary And Chemicals
Sectors We Cover  

- Township & Residential Complex
- Textiles And Readymade Garments
- Waste Management & Recycling
- Wood & Wood Products
- Water Industry (Packaged Drinking Water & Mineral Water)
- Wire & Cable
Objective

To get a detailed scenario of the industry along with its structure and classification
To provide a comprehensive analysis of the industry by covering aspects like:
  - Growth drivers of the industry
  - Latest market trends
  - Insights on regulatory framework
  - SWOT Analysis
  - Demand-Supply Situation
  - Foreign Trade
  - Porters 5 Forces Analysis
**Objective**

- To provide forecasts of key parameters which helps to anticipate the industry performance
- To help chart growth trajectory of a business by detailing the factors that affect the industry growth
- To help an entrepreneur/manager in keeping abreast with the changes in the industry
- To evaluate the competitive landscape of the industry by detailing:
  - Key players with their market shares
  - Financial comparison of present players
.Clientele

- Venturist/Capitalists
- Entrepreneur/Companies
- Industry Researchers
- Investment Funds
- Foreign Investors, NRI’s
- Project Consultants/Chartered Accountants
- Banks
- Corporates

[Click here for list]
Data Sources

- Secondary Research
  - Surveys
  - One-on-one Interactions
  - Databases

- Primary Research

- Industry Sources

- Online Research
  - Industry Journals

- Industry Experts
  - Industry Associations
  - Companies
Scope & Coverage

- Present Status (Indian & Global)
- Macro Environment
- Internal Market Analysis
- SWOT & Porters Analysis
- Demand Assessment
- Outlook & Forecasts (5Years)
Our research team comprises of experts from various financial fields:

- MBA’s
- Industry Researchers
- Financial Planners
- Research veterans with decades of experience
Structure of the Report

1. Overview
2. Market Analysis
   - 2.1 Growth Drivers
   - 2.2 Emerging Trends in the Industry
   - 2.3 Regulatory Framework
   - 2.4 SWOT Analysis
   - 2.5 Herfindahl–Hirschman Index (HHI)
3. Market Forecasts
4. Key Players
5. Key Financials and Analysis
   5.1 Contact Information
   5.2 Key Financials
   5.3 Financial comparison
6. Industry Size & Outlook
Take a look at **NIIR Project Consultancy Services** on #Street View

https://goo.gl/VstWkd
Contact us

Niir Project Consultancy Services

106-E, Kamla Nagar, Opp. Mall ST,
New Delhi-110007, India.

Email:npcs.ei@gmail.com, info@entrepreneurindia.co
Tel: +91-11-23843955, 23845654, 23845886
Mobile: +91-9097075054, 8800733955
Fax: +91-11-23845886

Website: www.entrepreneurindia.co, www.niir.org

Take a look at Niir Project Consultancy Services on #StreetView

https://goo.gl/VstWkd
Follow us

- https://www.linkedin.com/company/niir-project-consultancy-services
- https://www.facebook.com/NIIR.ORG
- https://www.youtube.com/user/NIIRproject
- https://twitter.com/npcs_in
- https://www.pinterest.com/npcsindia/